COURT-RULING filed Sep 7, 2026 at 20:00 ET
Eli Lilly's false advertising lawsuit against Mochi Health and compounding pharmacies survives in part. The court denied dismissal of the UCL conspiracy claim against the Aequita pharmacy defendants (allowing the case to proceed on the core theory that they knowingly participated in an unlawful corporate practice of medicine scheme), but dismissed the Lanham Act false advertising conspiracy claims against all defendants with prejudice (narrowing the scope of the case). This is a modest procedural win for Lilly, the case continues against key defendants on a significant state-law theory, but the federal false advertising conspiracy claims are permanently gone, limiting potential remedies and discovery scope. The ruling is a probability shifter, not a final outcome, and the financial exposure remains unquantified in the opinion.